Next Article in Journal
Erythrocyte Membrane-Coated Arsenic Trioxide-Loaded Sodium Alginate Nanoparticles for Tumor Therapy
Next Article in Special Issue
Hyaluronate Nanoparticles as a Delivery System to Carry Neuroglobin to the Brain after Stroke
Previous Article in Journal
Developing Clinically Relevant Dissolution Specifications for Oral Drug Products—Industrial and Regulatory Perspectives
Previous Article in Special Issue
Perivascular and Perineural Pathways Involved in Brain Delivery and Distribution of Drugs after Intranasal Administration
Open AccessReview

ABC Transporters at the Blood–Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas

by David Gomez-Zepeda 1,2,3,*,†, Méryam Taghi 1,2,3, Jean-Michel Scherrmann 1,2,3, Xavier Decleves 1,2,3,4,‡ and Marie-Claude Menet 1,2,3,5,*,‡
1
Inserm, UMR-S 1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France
2
Sorbonne Paris Cité, Université Paris Descartes, 75006 Paris, France
3
Sorbonne Paris Cité, Université Paris Diderot, 75013 Paris, France
4
UF Biologie du médicament et toxicologie, Hôpital Cochin, AP HP, 75006 Paris, France
5
UF Hormonologie adulte, Hôpital Cochin, AP HP, 75006 Paris, France
*
Authors to whom correspondence should be addressed.
Current affiliation: Laboratorio Nacional de Genómica para la Biodiversidad (Langebio)—Unidad de Genómica Avanzada, Cinvestav, Irapuato 36824, Guanajuato, Mexico.
These authors are co-last authors.
Pharmaceutics 2020, 12(1), 20; https://doi.org/10.3390/pharmaceutics12010020
Received: 14 November 2019 / Revised: 13 December 2019 / Accepted: 20 December 2019 / Published: 23 December 2019
(This article belongs to the Special Issue Drug Delivery to the Brain)
Drug delivery into the brain is regulated by the blood–brain interfaces. The blood–brain barrier (BBB), the blood–cerebrospinal fluid barrier (BCSFB), and the blood–arachnoid barrier (BAB) regulate the exchange of substances between the blood and brain parenchyma. These selective barriers present a high impermeability to most substances, with the selective transport of nutrients and transporters preventing the entry and accumulation of possibly toxic molecules, comprising many therapeutic drugs. Transporters of the ATP-binding cassette (ABC) superfamily have an important role in drug delivery, because they extrude a broad molecular diversity of xenobiotics, including several anticancer drugs, preventing their entry into the brain. Gliomas are the most common primary tumors diagnosed in adults, which are often characterized by a poor prognosis, notably in the case of high-grade gliomas. Therapeutic treatments frequently fail due to the difficulty of delivering drugs through the brain barriers, adding to diverse mechanisms developed by the cancer, including the overexpression or expression de novo of ABC transporters in tumoral cells and/or in the endothelial cells forming the blood–brain tumor barrier (BBTB). Many models have been developed to study the phenotype, molecular characteristics, and function of the blood–brain interfaces as well as to evaluate drug permeability into the brain. These include in vitro, in vivo, and in silico models, which together can help us to better understand their implication in drug resistance and to develop new therapeutics or delivery strategies to improve the treatment of pathologies of the central nervous system (CNS). In this review, we present the principal characteristics of the blood–brain interfaces; then, we focus on the ABC transporters present on them and their implication in drug delivery; next, we present some of the most important models used for the study of drug transport; finally, we summarize the implication of ABC transporters in glioma and the BBTB in drug resistance and the strategies to improve the delivery of CNS anticancer drugs. View Full-Text
Keywords: ABC transporters; blood–brain barrier (BBB); blood–cerebrospinal fluid barrier (BCSFB); arachnoid barrier (BAB); blood–brain tumor barrier (BBTB); glioma; drug delivery ABC transporters; blood–brain barrier (BBB); blood–cerebrospinal fluid barrier (BCSFB); arachnoid barrier (BAB); blood–brain tumor barrier (BBTB); glioma; drug delivery
Show Figures

Graphical abstract

MDPI and ACS Style

Gomez-Zepeda, D.; Taghi, M.; Scherrmann, J.-M.; Decleves, X.; Menet, M.-C. ABC Transporters at the Blood–Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas. Pharmaceutics 2020, 12, 20.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop